Chinese biopharma firms storm Nasdaq for IPOs
China’s BeiGene is eyeing a listing on the Nasdaq, with the drug maker tapping three banks for a $100m IPO.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: